Lung transplantation may prolong survival
and improve symptoms for patients with end-stage lung disease. However,
many shortcomings plague this procedure, including a lack of donor
organs, the need for lifelong immunosuppression, allograft rejection,
limited long-term patient survival, the high financial costs of the
surgery and subsequent care, and the constant threat of infection. Of
the infectious complications, cytomegalovirus (CMV) stands out as an
important agent causing significant morbidity and mortality.